News for May 2019

News Archive

The Ehlers-Danlos Society Awarded $50,000 Donation From Carnival Cruise Line Aboard the Launch of the New Carnival Sunrise The Ehlers-Danlos Society Awarded $50,000 Donation From Carnival Cruise Line Aboard the Launch of the New Carnival Sunrise

BALTIMORE, May 24, 2019 (Newswire.com) - The Ehlers-Danlos Society is honored to have been in attendance at the launch of the Carnival Cruise Line's newly renovated Carnival Sunrise. The ship's new godmother Kelly Arison, daughter of Carnival Corporation Chairman Micky Arison and his wife Madeleine, chose to raise awareness for The Ehlers-Danlos Society at this event. Kelly Arison is a strong advocate of the Ehlers-Danlos syndromes and hypermobility spectrum disorders, awarding The Ehlers-Danlos Society with a check for $50,000 in a presentation ceremony.

CARTANA launches In Situ Sequencing service for neuroscientists CARTANA launches In Situ Sequencing service for neuroscientists

Next generation In Situ Sequencing technology maps single cell gene expression levels within tissue section.

Scientists shed infrared light on brain-eating parasite to pave way for new treatment Scientists shed infrared light on brain-eating parasite to pave way for new treatment

Important new clues about how a common parasite found in cat faeces invades the human brain have been revealed by a team of scientists, using cutting-edge infrared microspectroscopy analysis.

Cancer Research UK to Test Targeted Drug in Pancreatic Cancer Cancer Research UK to Test Targeted Drug in Pancreatic Cancer

A dual kinase inhibitor* is entering a clinical trial for advanced pancreatic cancer in combination with gemcitabine as part of Cancer Research UK’s Combinations Alliance.

Verseon presents oral drug candidate for diabetic eye disease that could replace eye injections Verseon presents oral drug candidate for diabetic eye disease that could replace eye injections

One in three long-term diabetes patients will develop diabetic macular edema (DME), which can lead to blindness.Present treatments are recurring injections into the eye, which can lead to infection, inflammation and are rejected by many patients.Promising efficacy and pharmacokinetic data presented at ARVO 2019 show that Verseon’s oral drug candidate could become a real alternative to current eye injections.

Nobel Prize-winning stem cell researcher, Professor Shinya Yamanaka, visits CGT Catapult Nobel Prize-winning stem cell researcher, Professor Shinya Yamanaka, visits CGT Catapult

CGT Catapult welcomed Japanese Nobel Prize-winning stem cell researcher Professor Shinya Yamanaka to its development laboratories in London and manufacturing centre in Stevenage.

New open-source solution for the robust and reproducible analysis of High Content Screening data New open-source solution for the robust and reproducible analysis of High Content Screening data

Neuchâtel, Switzerland, 17 May 2019 – GladiaTOX, a new open-source solution for the analysis of high content screening (HCS) data in biomedical research, has been released on the online Bioconductor platform.

AI in life sciences still being held back by data issues and skills shortage, finds survey from The Pistoia Alliance AI in life sciences still being held back by data issues and skills shortage, finds survey from The Pistoia Alliance

Research exposes the need for more education and training to develop new data scientists and ensure successful AI implementation

Personalized “Eye-in-a-Dish” Models Reveal Genetic Underpinnings of Macular Degeneration Personalized “Eye-in-a-Dish” Models Reveal Genetic Underpinnings of Macular Degeneration

Age-related macular degeneration (AMD) is one of the most common causes of vision loss in people over age 65. The exact cause is unknown, but the fact that a family history of AMD increases a person’s risk for the condition suggests genetics play an important role. Using stem cells derived from six people, University of California San Diego School of Medicine researchers recapitulated retinal cells in the lab. This “eye-in-a-dish” model allowed them to look for genetic variants that might contribute to AMD.

Preventing cell death as novel therapeutic strategy for rheumatoid arthritis Preventing cell death as novel therapeutic strategy for rheumatoid arthritis

A collaborative study by research groups from the University of Cologne, VIB, Ghent University, the ?iomedical Sciences Research Center ‘Alexander Fleming’ in Athens and the University of Tokyo identified a new molecular mechanism causing rheumatoid arthritis. The researchers found that death of macrophages, an immune cell type, can trigger the disease. Moreover, they discovered how the protein A20 prevents macrophage death and protects against arthritis. These findings open up new possibilities for the treatment of this debilitating disease.

New report unveils a thriving service and supply sector for UK medicines discovery New report unveils a thriving service and supply sector for UK medicines discovery

Driving innovation into state-of-the-art technologies such as Artificial Intelligence and Complex Cell Models is key to maintaining the UK’s global competitiveness

Unlocking the Secrets of Sugar Chemistry Unlocking the Secrets of Sugar Chemistry

Iceni Diagnostics takes new approach to alleviate symptoms of Glycogen Storage Disease